×
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
×
What are you looking for?
Search for:
About Us
Overview
Our Leadership
Board of Directors
Scientific Advisory Board
Cell Manufacturing Advisory Board
Strategic Partners
Technology
Allogeneic Cell Therapy Platform
Oncolytic Virus Combinations
CD30 CAR-T Cell Therapy
Manufacturing
Pipeline
TT11X Allogeneic CD30 CAR EBVSTs
TT16 HER2 CAR Ts + CAdVEC
TT11 CD30 CAR Ts
TT11 CD30 CAR Ts + Nivolumab
Expanded Access
Scientific Publications
Investors & Media
Press Releases & Events
Interviews
Careers
Contact Us
Our Scientific Co-founder, Dr Malcolm Brenner Shares the Story about the Early Days of Tessa and its Scientific Foundation
by
tessathe
on
March 15, 2019
in
news-videos
<< Back to Press Releases & Events
Previous Reading
Tessa’s CFO, Desmond Lim spoke on Tessa’s plans for the future and the promise of Virus-Specific T Cell (VST) cancer immunotherapy on CNBC Capital Connection
Next Reading
Interview Series: In Pursuit of Cancer Cure: Conversations with Immunotherapy Advocates – Dr Malcolm Brenner
